AD is a growing market with an impressive pipeline of new products from current and future players in the field.

With the recent developments in the atopic dermatitis (AD) market, the field is becoming more competitive as novel therapies are soon anticipated to enter the market. This evolution may benefit AD ...

Sanofi’s next-generation experimental asthma drug failed to significantly reduce flare-ups in patients with ...

Responses to dupilumab (Dupixent) treatment were consistent across racial and ethnic groups in children with atopic ...

Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious ...

Attovia Therapeutics has completed an oversubscribed $90 million Series C financing, which the company plans to use along with existing cash and investments to advance its two lead pipeline candidates ...

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely monitored for its onset.

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...